Pancreatitis caused by tigecycline: A rare case report

Yinyin Guo1, Laiyuan Li2, Xia Song1 and Hui Zhao*

1 Lanzhou University Second Hospital, China
2 Department of Anorectal Surgery, Gansu Provincial Hospital, China

Abstract

Tigecycline is a broad-spectrum antibiotic, obtained by modifying earlier tetracycline, to prevent resistance mechanisms and is effective against many multidrug-resistant organisms [1,2]. According to the naranjo adverse drug reaction probability scale, tigecycline can cause pancreatitis during treatment [3]. Clinicians monitor patients for signs and symptoms related to amylase levels during treatment with tigecycline. We here report an adverse effect of tigecycline with a case of acute pancreatitis, which occurred on the 8th day of tigecycline administration and improved after its withdrawal.

Introduction

Tigecycline was approved on the market in 2005 by the US Food and Drug Administration (FDA). It is a broad-spectrum antibiotic that shows remarkable efficacy against many multiple drug-resistant (MDR) pathogens. The common side effects of tigecycline include nausea and vomiting. With the increasing detection rate of drug-resistant bacteria, the application of tigecycline increased significantly. Therefore, tigecycline-associated adverse reactions are increasing. In this report, we present a patient who was diagnosed with IgA nephropathy and pneumonia and presented with acute pancreatitis after the use of tigecycline.

Case presentation

On May 16, 2018, a 44-year-old male patient was admitted to our hospital with cough, expectoration and fever. He was diagnosed with community-acquired pneumonia. Then, the patient received moxifloxacin for the treatment of the infection. The patient had a history of IgA nephropathy and the long-term administration of hormones and cyclophosphamide. On the 7th day of hospitalization, the patient's infection was exacerbated, with an elevated white blood cell count (WBC) of 18.9*10^9/L, a procalcitonin (PCT) level of 1.920 ng/mL and a high temperature of 39.3°C. He was transferred to the intensive care unit (ICU) and started on mechanical ventilation due to severe pneumonia on May 23, 2018. According to his clinical symptoms and laboratory data, intravenous moxifloxacin, sulfamethoxazole and ganciclovir were administered. Continuous renal replacement therapy (CRRT) was performed because of his high blood creatinine level (540.8 μmol/L) and oliguria.

On the 2nd day after admission to the ICU, the patient's temperature gradually increased, and his clinical symptoms became significantly worse. We adjusted the anti-infection programme. The patient was treated with ceftoperazone, sulbactam, sulfamethoxazole and echinocandin. After 3 days of the anti-infection programme, his clinical symptoms improved. X-ray showed that his pulmonary infection was improved.

Unfortunately, the patient's oxygen saturation level dropped to 70% on his 8th day in the ICU. The blood culture and sputum culture were negative. Multiple drug-resistant Acinetobacter baumannii is one of the main pathogens that cause infections in the ICU. We adjusted the treatment plan to address an infection with Acinetobacter baumannii. The doctor added tigecycline to the treatment programme. Tigecycline was administered intravenously, with an initial dose of 100 mg and subsequent doses of 50 mg administered every 12 h. After 7 days of tigecycline treatment, the infection improved significantly, and the highest temperature was significantly lower than before. The patient initially tolerated this medicine without complaints of nausea or vomiting. However, physical examination found moderate tenderness in the upper abdomen. Laboratory analyses showed a marked increase in the level of amylase to 1250 U/L. Computed tomography (CT) scans suggested acute edema pancreatitis (Figure 1). Shortly after tigecycline discontinuation and symptomatic treatment, the patient's symptoms gradually improved. The patient's amylase level returned to 168 U/L on the 21st day following the discontinuation of tigecycline (Figure 2). Then, the patient returned to the nephrology department for treatment. We ordered the patient to go on a low-fat diet.

Discussion

Tigecycline is a glycylcycline with a broad spectrum of antibacterial activity [4]. Its indications include skin and soft tissue infections, complex abdominal infections, and community-acquired pneumonia in adults [5]. We do not recommend it for hospital-acquired pneumonia because of the high mortality rate [6]. In this case, the rationality of using tigecycline empirically for the treatment of severe pneumonia without specific aetiological identification was questionable.

At present, the detection rate of multi-drug resistant bacteria is increasing annually. Thus, tigecycline is a better choice than many other

*Correspondence to: Hui Zhao, Department of Pharmacy, Lanzhou University Second Hospital, 82 Cuiyingmen, Lanzhou, China. Email: ldeyzh@163.com

Key words: tigecycline, pancreatitis, case report

Received: September 27, 2019; Accepted: October 04, 2019; Published: October 07, 2019
The exact mechanism of tigecycline-induced pancreatitis is still unknown. Tigecycline is a derivative of minocycline. It causes adverse reactions that are similar to those associated with minocycline. Only a few studies have shown that the concentration of minocycline in the bile is much higher than that in the peripheral blood, which is the cause of pancreatitis [13]. Similarly, after a single 100 mg dose of tigecycline was administered, the concentrations of tigecycline in bile and the peripheral blood reached 75.2 mg/L (median) and 0.112 mg/L (median), respectively [14]. Furthermore, tetracycline can induce hypertriglyceridaemia, which is associated with pancreatitis [15]. Third, the mechanism may involve the formation of toxic metabolites.

Conclusions

Physicians should pay attention to clinical symptoms, clinical signs and the serum amylase concentration to monitor the development of pancreatitis. If necessary, abdominal CT images should be taken regularly after the administration of tigecycline.

Acknowledgments

The authors thank the patients for allowing us to publish these case reports.

Disclosure statement

The authors declare no conflict of interest.

References

1. Davido B, Shourick J, Makhoul S (2016) True incidence of tigecycline-induced pancreatitis: how many cases are we missing? J Antimicrob Chemother 71: 2994-2995. [Crossref]